Survival Outcomes among Human Epidermal Growth Factor Receptor 2- (HER2-) Positive Breast Cancer Patients at Kenyatta National Hospital.
Gloria TuweiAmsalu DeguPublished in: International journal of breast cancer (2021)
The 4-year survival rate for both early-stage and advanced-stage HER2-positive breast cancer in our setting is suboptimal when compared to existing outcome data from health care systems where trastuzumab is more widely available.
Keyphrases
- positive breast cancer
- epidermal growth factor receptor
- early stage
- healthcare
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- electronic health record
- induced pluripotent stem cells
- quality improvement
- pluripotent stem cells
- sentinel lymph node
- acute care
- adverse drug
- radiation therapy
- squamous cell carcinoma
- emergency department
- deep learning
- social media
- locally advanced
- affordable care act